Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC) - Sorbonne Université
Journal Articles American Heart Journal Year : 2018

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)

Thomas Bergmeijer
  • Function : Author
Jean-Luc Reny
  • Function : Author
Ruth Pakyz
  • Function : Author
Li Gong
  • Function : Author
Joshua Lewis
  • Function : Author
Eun-Young Kim
  • Function : Author
Daniel Aradi
  • Function : Author
Israel Fernandez-Cadenas
  • Function : Author
Richard Horenstein
  • Function : Author
Ming Ta Michael Lee
  • Function : Author
Ryan Whaley
  • Function : Author
Joan Montaner
  • Function : Author
Gian Franco Gensini
  • Function : Author
John Cleator
  • Function : Author
Kiyuk Chang
  • Function : Author
Lene Holmvang
  • Function : Author
Willibald Hochholzer
  • Function : Author
Dan Roden
  • Function : Author
Stefan Winter
  • Function : Author
Russ Altman
  • Function : Author
Dimitrios Alexopoulos
  • Function : Author
Ho-Sook Kim
  • Function : Author
Jean-Pierre Déry
  • Function : Author
Meinrad Gawaz
  • Function : Author
Kevin Bliden
  • Function : Author
Marco Valgimigli
Rossella Marcucci
  • Function : Author
Gianluca Campo
  • Function : Author
Elke Schaeffeler
  • Function : Author
Nadia Dridi
  • Function : Author
Ming-Shien Wen
  • Function : Author
Jae Gook Shin
  • Function : Author
Pierre Fontana
  • Function : Author
Betti Giusti
  • Function : Author
Tobias Geisler
  • Function : Author
Michiaki Kubo
  • Function : Author
Dietmar Trenk
  • Function : Author
Jolanta Siller-Matula
  • Function : Author
Jurriën ten Berg
  • Function : Author
Paul Gurbel
  • Function : Author
Jean-Sebastien Hulot
  • Function : Author
Braxton Mitchell
  • Function : Author
Matthias Schwab
  • Function : Author
Marylyn Deriggi Ritchie
  • Function : Author
Teri Klein
  • Function : Author
Alan Shuldiner
  • Function : Author

Abstract

The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke. Platelet inhibition by clopidogrel shows wide interpatient variability, and high on-treatment platelet reactivity is a risk factor for atherothrombotic events, particularly in high-risk populations. CYP2C19 polymorphism plays an important role in this variability, but heritability estimates suggest that additional genetic variants remain unidentified. The aim of the International Clopidogrel Pharmacogenomics Consortium (ICPC) is to identify genetic determinants of clopidogrel pharmacodynamics and clinical response.

Dates and versions

hal-03025815 , version 1 (26-11-2020)

Identifiers

Cite

Thomas Bergmeijer, Jean-Luc Reny, Ruth Pakyz, Li Gong, Joshua Lewis, et al.. Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, pp.152-159. ⟨10.1016/j.ahj.2017.12.010⟩. ⟨hal-03025815⟩
79 View
0 Download

Altmetric

Share

More